Walmart Inc. (NYSE:WMT) has taken the federal government to court as it disputes claims its pharmacist are helping fuel the opioids crisis. The lawsuit seeks to force the federal government to desist from saying the company’s pharmacists are responsible for the illegal distribution of opioids.
Walmart Lawsuit
The lawsuit comes on the Department of Justice and Drug Enforcement Agency's heels, holding Walmart pharmacists responsible for allegedly playing a pivotal role in the distribution of highly addictive opioids. The DOJ has already confirmed it intends to sue the retailer for not going far enough and continuing to fill opioid prescriptions.
The complaint has triggered a massive legal tussle over who should be blamed for the hundreds of thousands of deaths attributed to opioids overdose. Walmart finds itself in the current standoff on the fact that it operates over 5,000 in-store pharmacies, most of which dispense highly addictive opioids.
On its defense, the retailer insists its pharmacists are committed to helping address the opioid crisis rather than fuel it. It has also taken issue with certain DOJ officials who it insists are fixated at chasing headlines instead of finding a solution to the opioids crisis.
Walmart Opioids Stance
In its lawsuit, Walmart wants the court to dispute the DOJ and DEA over pharmacists' obligations under the controlled substance act. Walmart insists that its pharmacists have no right to turn down a prescription written by a DEA-licensed doctor. By doing so, the pharmacists would essentially be deciding without a medical license or knowledge.
Walmart wants the DEA and DOJ to focus on doctors that prescribe opioids. It also wants the court to rule that pharmacists have no right to second-guess licensed doctors' decisions. It also wants the court to rule that pharmacists write why filling a prescription written by a licensed doctor is appropriate.
Walmart first found itself at crossroads with authorities in 2016 when the U.S Attorney’s Office for the Eastern District of Texas began investigating the company. The DOJ stepped into the matter in 2018 following a dispute over the process.